FSH, Inhibin B Poor Predictors of Sperm Count After Cancer

Thursday, March 7, 2013 (Last Updated: 03/08/2013)

THURSDAY, March 7 (HealthDay News) -- Serum levels of follicle-stimulating hormone (FSH) and inhibin B are not good predictors of sperm levels in male survivors of childhood cancer, according to a study published online Feb. 19 in the Journal of Clinical Oncology.

Daniel M. Green, M.D., from the St. Jude Children's Research Hospital in Memphis, Tenn., and colleagues investigated the association of serum levels of FSH and inhibin B with sperm concentration in 275 adult male survivors of childhood cancer who had received gonadotoxic treatment placing them at risk of azoospermia.

Based on receiver operating characteristic analysis, the researchers chose 11.5 mIU/mL FSH and 31 ng/L inhibin B as cutoffs. Using these cutoffs to identify azoospermic survivors, they found that serum FSH levels had a specificity of 74.1 percent and a positive predictive value of 65.1 percent, while serum inhibin B levels had a specificity of 45.0 percent and a positive predictive value of 52.1 percent.

"Neither serum inhibin B nor FSH is a suitable surrogate for determination of sperm concentration in a semen sample," Green and colleagues conclude.

Full Text (subscription or payment may be required)

Specialties Hematology & Oncology
Internal Medicine

Health News Copyright © 2013 HealthDay. All rights reserved.


How Can I Help My Friend Going Through Cancer Treatment?
by OncoLink Editorial Team
September 05, 2014

7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015